GBA Presents: House of Gummy-!

stonedinvestor · Jul 11, 2024

stonedinvestor said:
LOOKS GOOD-
More...

My weekly list for you all is soaring! ////

stonedinvestor · Jul 11, 2024

stonedinvestor said:
UPDATE-
SLDB Solid Biosciences Inc.

$6.75 +0.88 (+14.99%)4:00 PM 07/08/24
NASDAQ | $USD | Post-Market: $6.75 5:03 PM
More...

vanzandt · Jul 11, 2024

poopy said:
You have 20-somethings in your bldg? Sounds pretty fancy. Rent controlled in Hartford.
More...

I bet we'll hear that Big Pete closed SOUN at $6.19.

stonedinvestor · Jul 11, 2024

CARR Carrier Global Corporation

$66.51 +2.91(+4.58%)11:19 AM 07/11/24
NYSE |$USD |Realtime

TrailerParkTed · Jul 11, 2024

TrailerParkTed said:
The $17s expiring tomorrow look interesting.
More...

Exiting !

stonedinvestor · Jul 11, 2024

stonedinvestor said:
I don't understand why Tempus AI gets such coverage today, assuming a recent IPO I missed, and we cannot get the same thing for RBRK.

Rubrik to benefit the most from CDK Global cyberattack: Cantor Fitzgerald
NewsFri, Jun. 21

RBRK Rubrik, Inc.- Common man!

$32.01-0.75(-2.29%)4:00 PM 07/08/24
More...

Feels to me like she wants to explode up. Or am I wishing?????

Get In!!!!-->RBRK Rubrik, Inc.
$33.97 0.78(+2.35%)11:22 AM 07/11/24
NYSE |$USD |Realtime

vanzandt · Jul 11, 2024

stonedinvestor said:
Loading Dock-->SLDB Solid Biosciences Inc.

$8.37-0.14 (-1.70%)10:33 AM 06/14/24
NASDAQ | $USD | Realtime
More...

Back to even.

stonedinvestor · Jul 11, 2024

No doubt the Lizard King thinks he'll find me. You were wondering why I pushed my exit up to Friday from sat...

I know he is on the way....

He can smell the fear.

stonedinvestor · Jul 11, 2024

Goldman Sachs raises concerns about the AI trade that markets have rallied behind

stonedinvestor · Jul 11, 2024

stonedinvestor said:
THE BIO-KING REPORT: SLDB

Fintel reports that on June 24, 2024, Leerink Partners upgraded their outlook for Solid Biosciences (NasdaqGS:SLDB) from Market Perform to Outperform.

Analyst Price Forecast Suggests 160.53% Upside

As of June 12, 2024, the average one-year price target for Solid Biosciences is 16.83. The forecasts range from a low of 12.12 to a high of $21.00. The average price target represents an increase of 160.53%

All of this does not tell the whole story though:

1- Shares of Solid Bio spent two years in free fall from early 2021 to late 2023.

2- Chasing SRPT: William Blair analyst Tim Lugo says Solid Bio could be a fast follower in Duchenne muscular dystrophy. Sarepta Therapeutics(SRPT) has the only approved gene therapy on the market for the disease, which primarily affects boys and causes progressive muscle weakness.

3-Solid Bio's drug works by helping a patient's body make a miniature version of the dystrophin protein. Dystrophin keeps muscles intact, but it's missing in patients with Duchenne muscular dystrophy. In mice, Solid Bio's gene therapy led to high levels of dystrophy expression.

"Given the 100% expression viewed in several areas of the mouse model, we believe expression data should be strong, and if the safety profile is clean, we would expect this to be a catalyst for shares to spike severalfold," Lugo said.

4- Now when this analyst was talking about severalfold (great word) Solid was $13. // We are now getting it for much less.. sEveralfold from $13...= $36//<--- GBA TARGET***

Solid Bio is working on a treatment for catecholaminergic polymorphic ventricular tachycardia, or CPVT. This inherited disorder causes sudden heart rhythm disturbances, also called arrhythmias, in healthy children.

CPVT is "a potentially even larger driver of value than DMD given the company's lead position in this deadly disease that impacts 20,000 people in the United States alone," he said. "Solid's program also holds several possibilities for fast-to-market clinical trial design."

<<< Alright all of that is well and good but there's more...

A) We just joineD the Russell 3000

B) FDA's Sarepta decision 'positive' for gene therapy, STATNews reports » 06/21 SRPT, SLDB<-----

C) Piper sees opportunity for Solid Biosciences after broad Elevidys approval » 06/21 SLDB, SRPT<------

D) Solid Biosciences expects cash to fund strategic priorities into 2026 » 05/15 SLDB

E) Pfizer had a setback in this same field... and that ignited SRPT...
Sarepta gains after Pfizer’s late-stage setback for Duchenne therapy
NewsThu, Jun. 13

F) Pfizer DMD gene therapy miss paves way for Sarepta, Solid Biosciences, says Citi » 06/13 SRPT, SLDB, PFE

Ok so SRPT already fired /// SLDB is up next.... (Hopefully)

I will be buying Solid this Monday or Tues.

More...

Thank You Stoney!